• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
COVID-19 Management

Initial Results from WHO COVID-19 Solidarity Trial: The Effectiveness of Remdesivir, Hydroxychloroquine, Lopinavir, and Interferon-β1a

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • The Solidarity trial is a multinational Phase III-IV clinical trial designed to compare 4 treatments for hospitalized people with severe COVID-19
  • Pan et al. (MedRxiv, 2020) present interim results from the Solidarity trial for the following
    • Remdesivir | Hydroxychloroquine | Lopinavir | Interferon-β1a

METHODS:

  • Multinational open-label clinical randomized trial
    • 405 hospitals in 30 countries
  • Participants
    • COVID-19 inpatients
  • Interventions
    • Remdesivir
    • Hydroxychloroquine
    • Lopinavir
      • Fixed-dose combination with Ritonavir
    • Interferon-β1a
      • Initially subcutaneous with Lopinavir
    • Local standard-of-care
  • Study design
    • Patients were randomized equally between whichever study drugs were locally available vs control
    • Analysis was with intention-to-treat with pairwise comparisons of each study drug vs its controls
    • Rate ratios (RRs) are stratified for age and ventilation at entry
  • Primary outcome
    • In-hospital mortality

RESULTS:

  • 11,266 adults were randomized
    • Remdesivir: 2750 patients
    • Hydroxychloroquine: 954 patients
    • Lopinavir: 1411 patients
    • Interferon plus Lopinavir: 651 patients
    • Only Interferon: 1412 patients
    • Standard care: 4088 patients
  • Mortality
    • Reported deaths: 1253 patients | Median day 8 (IQR 4 to 14)
    • 28-day mortality: 12%
      • If already ventilated at randomization: 39%
      • Otherwise: 10%
  • Death rate ratios (drug vs control)
    • Remdesivir: RR 0.95 (95% CI, 0.81 to 1.11; p=0.05)
    • Hydroxychloroquine: RR 1.19 (95% CI, 0.89 to 1.59; p=0.23)
    • Lopinavir: RR 1.00 (95% CI, 0.79 to 1.25; p=0.97)
    • Interferon: RR 1.16 (95% CI, 0.96 to 1.39; p=0.11)
  • There was no clear reduction for the following
    • Mortality (in unventilated patients or any other subgroups)
    • Initiation of ventilation
    • Hospitalization duration

CONCLUSION:

  • In the multinational WHO Solidarity trial, remdesivir, hydroxychloroquine, lopinavir and interferon had little or no effect on mortality, length of hospitalization, and ventilation requirement
  • The data is published in MedRxiv which means the data is not yet peer reviewed but was released for public analysis
  • The authors conclude

The unpromising overall findings from the regimens tested suffice to refute early hopes, based on smaller or non-randomized studies, that any will substantially reduce inpatient mortality, initiation of ventilation or hospitalisation duration

Narrower confidence intervals would be helpful (particularly for remdesivir), but the main need is for better treatments

Solidarity is still recruiting about 2000 patients per month, and efficient factorial designs will allow it to assess further treatments, such as immune-modulators and specific anti-SARSCov-2 monoclonal antibodies

Learn More – Primary Sources:

Repurposed antiviral drugs for COVID-19–interim WHO SOLIDARITY trial results

Get COVID-19 Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All COVID-19 Management Posts
Next >

Related ObG Topics:

ACTT-1 Remdesivir RCT: Preliminary Results Now Published
COVID-19 Treatment RCT Results: Combination Interferon beta-1b, Lopinavir-Ritonavir and Ribavirin
Meta-analysis of Hydroxychloroquine for the Treatment of COVID-19
Remdesivir for COVID-19: RCT Results from 10 Hospitals in China

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site